injectable tirzepatide in Mountain View, WY 1 and GIP therapy Tirzepatide Flex-Dose 1 mL Injectable

Neelam, Khatkar A, Sharma KK

These patterns can be missed when your notes are just in a paper journal or scattered phone memos

The medication is also approved for weight management in individuals with obesity or overweight with associated health conditions

Feeling better than I have in years

E N D Presentation Transcript GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2 Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks Effects of GLP-1 agonists on inflammatory markers GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) E-selectin was not significantly reduced C-reactive protein has also been associated with increased cardiovascular disease Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus